Ritonavir News and Research

RSS
Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
An algorithm to predict host cleavage targets of SARS-CoV-2 3CLPro

An algorithm to predict host cleavage targets of SARS-CoV-2 3CLPro

PAXLOVID shown to be highly effective against all SARS-CoV-2 variants

PAXLOVID shown to be highly effective against all SARS-CoV-2 variants

Study shows inequalities in addressing post-acute neurological manifestations of COVID-19

Study shows inequalities in addressing post-acute neurological manifestations of COVID-19

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

UK government signs two new deals to combat the Omicron variant

UK government signs two new deals to combat the Omicron variant

Study suggests efficacy of SARS-CoV-2 main protease inhibitors is not compromised in current COVID-19 variants

Study suggests efficacy of SARS-CoV-2 main protease inhibitors is not compromised in current COVID-19 variants

Structure-guided virtual screening identifies novel SARS-CoV-2 Mpro inhibitors

Structure-guided virtual screening identifies novel SARS-CoV-2 Mpro inhibitors

Success of covid antiviral pills hinges on access to speedy and accurate tests

Success of covid antiviral pills hinges on access to speedy and accurate tests

Comparing effectiveness of virus and patients-centered strategies to reduce COVID-19 mortality

Comparing effectiveness of virus and patients-centered strategies to reduce COVID-19 mortality

Oral SARS-CoV-2 Mpro inhibitor for therapeutic use

Oral SARS-CoV-2 Mpro inhibitor for therapeutic use

Can targeting autophagy become a new approach to COVID-19 treatment?

Can targeting autophagy become a new approach to COVID-19 treatment?

UK government announces deals to secure two new COVID-19 treatments

UK government announces deals to secure two new COVID-19 treatments

A survey on computational methods in discovering protein inhibitors of SARS-CoV-2

A survey on computational methods in discovering protein inhibitors of SARS-CoV-2

Potential covalent SARS-CoV-2 spike protein inhibitors

Potential covalent SARS-CoV-2 spike protein inhibitors

Potential pancoronavirus fusion inhibitors that are effective against SARS-CoV-2 variants

Potential pancoronavirus fusion inhibitors that are effective against SARS-CoV-2 variants

Pfizer moves towards an oral anti-COVID-19 therapy

Pfizer moves towards an oral anti-COVID-19 therapy

Cyperus rotundus medicinal plant shows promise for novel COVID-19 therapeutics

Cyperus rotundus medicinal plant shows promise for novel COVID-19 therapeutics

Are COVID-19 medications safe in pregnancy?

Are COVID-19 medications safe in pregnancy?

Facets of SARS-CoV-2 infection and animal models

Facets of SARS-CoV-2 infection and animal models

ANTICOV clinical trial to test new treatment for people with mild-to-moderate COVID-19 in Africa

ANTICOV clinical trial to test new treatment for people with mild-to-moderate COVID-19 in Africa